X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs GLENMARK PHARMA - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD GLENMARK PHARMA WYETH LTD/
GLENMARK PHARMA
 
P/E (TTM) x 27.7 12.2 227.2% View Chart
P/BV x 5.3 3.2 166.0% View Chart
Dividend Yield % 1.3 0.4 340.0%  

Financials

 WYETH LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    WYETH LTD
Mar-13
GLENMARK PHARMA
Mar-17
WYETH LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,044993 105.2%   
Low Rs818729 112.2%   
Sales per share (Unadj.) Rs298.6325.5 91.7%  
Earnings per share (Unadj.) Rs57.239.3 145.7%  
Cash flow per share (Unadj.) Rs58.448.7 120.0%  
Dividends per share (Unadj.) Rs17.002.00 850.0%  
Dividend yield (eoy) %1.80.2 786.1%  
Book value per share (Unadj.) Rs249.5159.2 156.7%  
Shares outstanding (eoy) m22.72282.17 8.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.12.6 117.9%   
Avg P/E ratio x16.321.9 74.2%  
P/CF ratio (eoy) x15.917.7 90.1%  
Price / Book Value ratio x3.75.4 69.0%  
Dividend payout %29.75.1 583.5%   
Avg Mkt Cap Rs m21,157242,991 8.7%   
No. of employees `0000.513.0 3.8%   
Total wages/salary Rs m40016,408 2.4%   
Avg. sales/employee Rs Th13,787.47,083.9 194.6%   
Avg. wages/employee Rs Th813.01,265.4 64.3%   
Avg. net profit/employee Rs Th2,643.3855.1 309.1%   
INCOME DATA
Net Sales Rs m6,78391,857 7.4%  
Other income Rs m353374 94.4%   
Total revenues Rs m7,13692,230 7.7%   
Gross profit Rs m1,61720,367 7.9%  
Depreciation Rs m272,644 1.0%   
Interest Rs m62,373 0.2%   
Profit before tax Rs m1,93815,724 12.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-5-810 0.6%   
Tax Rs m6323,827 16.5%   
Profit after tax Rs m1,30111,088 11.7%  
Gross profit margin %23.822.2 107.5%  
Effective tax rate %32.624.3 134.1%   
Net profit margin %19.212.1 158.8%  
BALANCE SHEET DATA
Current assets Rs m6,98468,746 10.2%   
Current liabilities Rs m2,05627,027 7.6%   
Net working cap to sales %72.645.4 160.0%  
Current ratio x3.42.5 133.5%  
Inventory Days Days9985 116.8%  
Debtors Days Days2496 25.1%  
Net fixed assets Rs m24424,132 1.0%   
Share capital Rs m227282 80.5%   
"Free" reserves Rs m5,44144,643 12.2%   
Net worth Rs m5,66844,925 12.6%   
Long term debt Rs m2545,363 0.1%   
Total assets Rs m7,901117,639 6.7%  
Interest coverage x353.37.6 4,633.5%   
Debt to equity ratio x01.0 0.4%  
Sales to assets ratio x0.90.8 110.0%   
Return on assets %16.511.4 144.5%  
Return on equity %22.924.7 93.0%  
Return on capital %34.019.1 177.8%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1556,152 0.0%   
Fx outflow Rs m2,6778,084 33.1%   
Net fx Rs m-2,66248,068 -5.5%   
CASH FLOW
From Operations Rs m9236,574 14.0%  
From Investments Rs m317-7,124 -4.4%  
From Financial Activity Rs m-4815,432 -8.9%  
Net Cashflow Rs m7591,992 38.1%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 6.9 163.8%  
FIIs % 7.2 34.4 20.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 10.5 289.5%  
Shareholders   21,978 56,727 38.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   PLETHICO PHARMA  BIOCON LTD  FULFORD INDIA  ALKEM LABORATORIES  DIVIS LABORATORIES  

Compare WYETH LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - SHASUN PHARMA COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS